Form 4: Procept BioRobotics EVP Alaleh Nouri Reports Stock Transactions

Alaleh Nouri, EVP, CLO, and Corporate Secretary of Procept BioRobotics, reports acquisition and disposal of common stock and stock options.

Summary

• On March 6, 2024, Alaleh Nouri, EVP, CLO, and Corporate Secretary of Procept BioRobotics Corp, reported transactions involving the company's stock.
• Nouri acquired 18,311 shares of common stock in the form of restricted stock units (RSUs) at a price of $0.
• These RSUs vest in equal installments on the anniversary of March 5, 2024, over a three-year period, contingent upon continued employment.
• Nouri also sold 2,749 shares of common stock at a weighted average price of $46.67 to cover tax withholding obligations related to the vesting of RSUs granted on February 16, 2023.
• Additionally, Nouri acquired stock options for 15,949 shares of common stock at an exercise price of $47.17, which vest monthly from March 5, 2024, over a four-year period, contingent upon continued employment.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, as required by the SEC. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The vesting schedules for RSUs and stock options are typical for employee compensation packages in the biotech industry.
• Similar filings can be observed for executives at comparable companies like Intuitive Surgical (ISRG) and Stryker (SYK).

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership of shares.
• Employees may be impacted as the vesting of RSUs and stock options are tied to continued employment.

Key Dates